Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment ; volume:8 ; number:1 ; day:3 ; month:12 ; year:2018 ; pages:1-14 ; date:12.2018
Scientific reports ; 8, Heft 1 (3.12.2018), 1-14, 12.2018
- Creator
-
Chodorge, Matthieu
Celeste, Anthony J.
Grimsby, Joseph
Konkar, Anish
Davidsson, Pia
Fairman, David
Jenkinson, Lesley
Naylor, Jacqueline
White, Nicholas
Seaman, Jonathan C.
Dickson, Karen
Kemp, Benjamin
Spooner, Jennifer
Rossy, Emmanuel
Hornigold, David C.
Trevaskis, James L.
Bond, Nicholas J.
London, Timothy B.
Buchanan, Andrew
Vaughan, Tristan
Rondinone, Cristina M.
Osbourn, Jane K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-35869-4
- URN
-
urn:nbn:de:101:1-2019011317224448512593
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
09.09.190728635, 12:30 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chodorge, Matthieu
- Celeste, Anthony J.
- Grimsby, Joseph
- Konkar, Anish
- Davidsson, Pia
- Fairman, David
- Jenkinson, Lesley
- Naylor, Jacqueline
- White, Nicholas
- Seaman, Jonathan C.
- Dickson, Karen
- Kemp, Benjamin
- Spooner, Jennifer
- Rossy, Emmanuel
- Hornigold, David C.
- Trevaskis, James L.
- Bond, Nicholas J.
- London, Timothy B.
- Buchanan, Andrew
- Vaughan, Tristan
- Rondinone, Cristina M.
- Osbourn, Jane K.
- SpringerLink (Online service)
Other Objects (12)
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus
Glucagon-like peptide 1 (GLP-1)
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
WT1 peptide analogue WT1-126Y enhances leukemia lysis
C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study
Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
Gene Therapy Targeting PCSK9
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus
Glucagon-like peptide 1 (GLP-1)
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
WT1 peptide analogue WT1-126Y enhances leukemia lysis
C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study
Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
Gene Therapy Targeting PCSK9
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus
Glucagon-like peptide 1 (GLP-1)
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
WT1 peptide analogue WT1-126Y enhances leukemia lysis
C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study
Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism